Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella, Grazia Daniela
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). [electronic resource] - Trials 04 2019 - 191 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1745-6215
10.1186/s13063-019-3259-x doi
Activities of Daily Living
Alzheimer Disease--drug therapy
Brain--drug effects
Clinical Trials, Phase II as Topic
Cognition--drug effects
Double-Blind Method
Glucagon-Like Peptide-1 Receptor--metabolism
Glucose--metabolism
Humans
Hypoglycemic Agents--adverse effects
Liraglutide--adverse effects
Memory--drug effects
Multicenter Studies as Topic
Neuroprotective Agents--adverse effects
Randomized Controlled Trials as Topic
Severity of Illness Index
Time Factors
Treatment Outcome
United Kingdom
Glucagon-Like Peptide-1 Receptor Agonists
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). [electronic resource] - Trials 04 2019 - 191 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1745-6215
10.1186/s13063-019-3259-x doi
Activities of Daily Living
Alzheimer Disease--drug therapy
Brain--drug effects
Clinical Trials, Phase II as Topic
Cognition--drug effects
Double-Blind Method
Glucagon-Like Peptide-1 Receptor--metabolism
Glucose--metabolism
Humans
Hypoglycemic Agents--adverse effects
Liraglutide--adverse effects
Memory--drug effects
Multicenter Studies as Topic
Neuroprotective Agents--adverse effects
Randomized Controlled Trials as Topic
Severity of Illness Index
Time Factors
Treatment Outcome
United Kingdom
Glucagon-Like Peptide-1 Receptor Agonists